Received Mar 3, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| DTAP | DTAP (DAPTACEL) | SANOFI PASTEUR | UNK | — | — |
| FLU3 | INFLUENZA (SEASONAL) (FLUBLOK) | SANOFI PASTEUR | UNK | — | — |
| FLU3 | INFLUENZA (SEASONAL) (FLUZONE) | SANOFI PASTEUR | UNK | — | — |
| HIBV | HIB (ACTHIB) | SANOFI PASTEUR | UNK | — | — |
| MEN | MENINGOCOCCAL (NO BRAND NAME) | UNKNOWN MANUFACTURER | UNK | — | — |
vaccines were administered post excursion with no reported adverse event; Initial information received on 19-Feb-2025 regarding an unsolicited valid non-serious case received from a other health professional. This case involves an unknown age/gender patient who was administered MENINGOCOCCAL A-C-Y-W135 (T CONJ) VACCINE [MENQUADFI], INFLUENZA QUADRIVALENT RECOMBINANT VACCINE [FLUBLOK], INFLUENZA QUADRIVAL A-B MULTIDOSE VACCINE PRESERVED [FLUZONE], HIB (PRP/T) VACCINE [ACT-HIB] and DIPHTHERIA-15/TETANUS/5 AC PERTUSSIS VACCINE [DAPTACEL] vaccines post excursion with no reported adverse event. The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided. On an unknown date, the patient received a dose of suspect MENINGOCOCCAL A-C-Y-W135 (T CONJ) VACCINE, solution for injection, DIPHTHERIA-15/TETANUS/5 AC PERTUSSIS VACCINE, Suspension for injection, lHIB (PRP/T) VACCINE, Powder and solvent for solution for injection, INFLUENZA QUADRIVAL A-B MULTIDOSE VACCINE PRESERVED, Suspension for injection and INFLUENZA QUADRIVALENT RECOMBINANT VACCINE (formulation: unknown) post excursion with no adverse event (poor quality product administered) (latency same day) (dose, formulation, strength, route, lot and expiry: unknown) in unknown administration site for prophylactic vaccination. Reportedly, there were no previous excursion, human error not involved. not covered by extended stability This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.; Sender's Comments: US-SA-2025SA054065: US-SA-2025SA054013: US-SA-2025SA054381: US-SA-2025SA054097: US-SA-2025SA054040: US-SA-2025SA053939: